Pulse Biosciences: Promising Catheter Technology, Weak Risk-Reward For Now

Myriam Alvarez3.33K FollowersFollow5ShareSavePlay(10min)CommentsSummaryPulse Biosciences’ nsPFA platform shows promising AFib catheter data. This supports management’s decision to prioritize their cardiac program.In my view, this is easily PLSE’s main value driver. Plus, the AFib catheter system has IDE clearance and has already enrolled its first US pivotal patients.In the long term, this may give PLSE a nice position within a large and growing electrophysiology market.Also, PLSE’s thyroid nodule program adds some optionality to the stock. They’ve reported some encouraging efficacy and safety data and an R&D collaboration.Unfortunately, I don’t think its premium valuation gives new investors a compelling risk-reward, which is why I remain neutral at these levels. IURII KRASILNIKOV/iStock via Getty Images Pulse Biosciences, Inc. (PLSE) is a bioelectric medicine company working on its proprietary nPulse technology (nsPFA). This approach allows them to deliver nano pulses to clear targeted cells with a non-thermal approach. The company's priority isThis article was written byMyriam Alvarez3.33K FollowersFollowMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking Alpha. Our analyses are conducted independently, and we adhere to Seeking Alpha's Shared Association Guidelines.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.